List of Therapeutic Companies in Australia - 64

Antibody-based therapeutics for tissue repair applications

Development of antibodies from phage display discovery

AdAlta (ASX:1AD) is the pioneer of a novel technology platform that mimics the shape and engineers key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease. AdAlta is utilising the power of its i-body technology platform to develop a pipeline of i-bodies (drugs), with an initial focus on treating fibrotic diseases.

Anatara Lifesciences is developing evidence-based solutions for gastrointestinal diseases in humans and animals. GaRP is the working name for Anatara’s evidence based complementary medicines using unique formulations of bromelain, an enzyme extracted from pineapple stems along with other synergistic GRAS components. The combination and coating of these GaRP components have a beneficial effect on the physiology of the gastrointestinal lining, a positive influence on the microbiome (homeostasis & metabolites) and allows absorption of components in targeted areas of the gastrointestinal tract. GaRP’s multimodal activity provides a versatility for tailoring the components to various indications. Human Applications GaRP's human formulation is a microbiome-targeted multi-component complementary medicine that has been designed to address the primary underlying factors associated with gastrointestinal disorders such as IBS and IBD. Our formulation is positioned as an adjunct to existing therapies and is currently being tested in a double-blinded, placebo-controlled human clinical trial for safety and efficacy. For further information on our human development plans, visit our webpage: https://anataralifesciences.com/products-pipeline/human-applications/. Animal Applications Anatara developed Detach® for the control of scour (diarrhoea) in pigs which was approved the Australian Pesticides and Veterinary Medicines Authority (APVMA). Detach® has been shown to reduce post-weaning diarrhoea and provide similar protection to antimicrobial agents, such as zinc oxide. BONIFF is a revised formulation of Detach® that can be applied to dry feed for piglets after weaning for a simplified feeding process. ANR-pf is a proprietary enriched formulation for poultry in water, providing a quick and flexible dosing method on-farm. For further information on our Detach® development plans, visit our webpage: https://anataralifesciences.com/products-pipeline/animal-applications/.

Anteris Technologies is a structural heart company focused on developing innovative solutions to the biggest challenges facing aortic stenosis patients and their physicians. Our DurAVR™ Transcatheter Heart Valve (THV) System is designed for younger patients who need a heart valve that will last their lifetime. DurAVR™ THV is a unique, single-piece valve and its first-in-class biomimetic design replicates the normal blood flow of a healthy human aortic valve. | $AVR | ASX: AVR | #DurAVR #ADAPT #structuralheart #TAVR #TAVI #cardiology

Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.

Arovella Therapeutics (ASX: ALA) is the only Australian biotech developing an iNKT cell therapy platform to create therapies for people to live longer, healthier lives.

Founded in 2003, Base Pharmaceuticals has been a beacon of innovation and quality in the healthcare industry. Our logo, "Reason for Being," symbolizes our dedication to providing life-saving and life-enhancing pharmaceutical solutions. We are committed to improving the quality of life for individuals and communities across North India.

Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) and traded on the OTC markets in the U.S.A. with business presence in Australia, China, Japan and the USA. It currently has four core businesses – cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Beroni Group’s overall strategic goal is to become a world’s leading enterprise in the biotechnology, life sciences, and environmental science industries.

BioDiem is a biopharmaceutical company that focuses on developing and commercialising vaccines and infectious disease therapies.

BiomeBank's mission is to treat and prevent disease by restoring gut microbial ecology

Bionomics is a global, clinical stage biopharmaceutical company focused on leveraging its ion channel and chemistry platform to develop novel and first-in-class ion channel modulators to treat patients suffering from central nervous system disorders and cancer.

Carina Biotech An Australian clinical stage immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. Carina are working towards producing broad-spectrum CAR-T therapies that can be used to treat multiple solid cancers yet are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing. We are working to… 1. Expand the clinical indications for T cell therapies 2. Improve the commercial viability of T cell therapies by developing supporting technologies that make T cell therapies more effective or economically viable Headquartered in Adelaide, South Australia, Carina has strong T cell R&D capability across a network of research providers and collaborators including leading scientists at the UniSA, the Women's & Children's Hospital in Adelaide, the University of Adelaide, the Royal Prince Alfred Hospital in NSW and the Seattle Children's Hospital in the United States.

Cartherics works to create precisely-defined immunotherapy treatments to combat a variety of cancers. We take a multi-platform approach combining the best components of immune defences utilising gene editing and CAR technology. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Born in 2005 as a biotech company, Anagenics (ASX: AN1) has evolved into a growing beauty, health and wellness business with a strong portfolio of functional skin, hair and wellness brands. We own a beauty distribution company, BLC Cosmetics, which distributes some of the leading names in the beauty and skincare sector. We also develop, manufacture and market two beauty and wellness brands; Uspa and evolis. To learn more, please visit anagenics.com

Celosia Therapeutics is a privately held pre-clinical stage gene therapy company, developing solutions for neurodegenerative diseases that have limited alternative therapeutic options.

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression. To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development and commercialization of the most innovative and promising cell therapies.chm

Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products. It was founded in 2010 and is based in Australia. The company focuses on addressing the growing need for the use of radiopharmaceutical therapies in the treatment of serious diseases.

CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, CSL Plasma and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

Currus Biologics is utilising its proprietary BEAT technology to develop CAR-T cell therapies for the treatment of solid tumour cancers, traditionally difficult to treat with current CAR-T cell therapies. Currus Biologics’ proprietary Bispecific Engagers of Antigen Presenting Cells and T cells (BEAT) technology overcomes many of the challenges presented when treating solid tumours with traditional CAR-T cell therapy, demonstrating CAR-T cell proliferation and persistence, CAR-T cell trafficking to the tumour and immunological memory extending to additional antigens. Currus Biologics is a privately held biotechnology company based in Melbourne, Australia.

Cyclomedica is a global leader in nuclear medicine and molecular imaging, focusing on innovative diagnostic solutions for respiratory diseases. As a subsidiary of Cyclopharm Limited, the company is known for its flagship product, Technegas®, a lung imaging agent that enables high-resolution ventilation scans for conditions such as pulmonary embolism and COPD. Founded on advancements in radiopharmaceutical technology, Cyclomedica aims to improve patient outcomes through early intervention and enhanced care protocols. The company has a strong global presence, having expanded into various markets since its inception. It offers additional products like Pertechnegas, a specialized diagnostic application, and Galligas, a PET imaging variant. Cyclomedica also employs 3D SPECT imaging to enhance diagnostic accuracy in nuclear pulmonology. With ongoing research initiatives and a strategic focus on U.S. market expansion, Cyclomedica continues to advance its mission of elevating standards in respiratory disease management.

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors. Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in severe complications arising from COVID-19 (Phase 2) are currently ongoing. Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), critical limb ischemia, idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Diag-Nose.io, founded in 2020 and headquartered in Melbourne, Australia, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions. Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies. The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.

Emyria Limited is a clinical services and drug development company focused on improving patient outcomes in neuroscience and mental health via a unique business model: Emyria Clinics: Deliver evidence-based and emerging therapies for mental health and other unmet needs across multiple sites. Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients. Emyria Data is used to improve Emyria’s distinct therapy and drug development programs. Emyria Drug Discovery: One of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia and a suite of high potency Ultra-Pure cannabinoids currently being evaluated as in clinical trials for a range of mental health and select neuroscience indications.

ENA Respiratory is a clinical stage pharmaceutical company, developing INNA-051, a topical, broad spectrum antiviral immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. ACCEPTABLE USE POLICY We welcome your comments on our page but we ask that you help us comply with the Therapeutic Goods Advertising Code. Please consider these guidelines before commenting. We will remove any comments that may result in us breaching the Code. We love when you comment and tag your friends and family on our posts but we ask that you do not: • endorse our product if you are: o an employee or contractor of a government authority, a hospital or a healthcare facility o a health practitioner, health professional or medical researcher o involved with the production, sale, supply or marketing of our product o not using your own name on this social media platform • imply that a government authority, a hospital or a healthcare facility endorse our product • make comments about how a product works for you outside of its intended purpose, as these comments can be dangerous or misleading - our products are developed for particular purposes, as stated on the label and/or in our advertising • make comments about serious conditions, diseases, ailments or defects, such as comments about how a product helped with your treatment of a serious disease or how it will relieve a tagged person's serious condition We also have an obligation to make sure any advertisements we make, including endorsements and testimonials, are not misleading. Therefore we promise to disclose: • where a person has been, or will be, compensated for making a testimonial • where we have actors making the testimonial, such as in cases where the original person who made the testimonial does not want to appear in our advertisement • where the person making the testimonial is an immediate family member of anyone employed by our company.

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.

ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect. The company is developing a bio-selected RNA virus to induce tumour inflammation and achieve immune cell infiltration via the RIG-I pathway. The targets for this approach are Ovarian, Head & Neck and those indications which present with liver metastases such as Colorectal, Hepatocellular carcinoma and Pancreatic cancer. The approach includes combination therapy with Immune Checkpoint Inhibitors and CAR-T agents using bio-selected RNA virus. The company founders, Malcolm McColl and Prof. Darren Shafren, were Managing Director and CSO of Viralytics, an ASX listed oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million. The ImmVirX team includes key management and researchers from Viralytics and is based at the former Viralytics laboratory facilities in Newcastle Australia.

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies.

Incannex is a clinical-stage pharmaceutical development company focused on discovering and developing life-changing medicines for patients struggling with serious, chronic diseases and limited treatment options. A leader in innovating proprietary cannabinoid pharmaceuticals and psychedelic-based therapies, we are developing medicines with the potential to alter the lives of patients suffering from obstructive sleep apnea (OSA), generalized anxiety disorder (GAD), and inflammatory disorders such as rheumatoid arthritis (RA). Working together in these relatively new fields with clinical, scientific, and drug development experts, we are efficiently innovating big solutions that are specifically designed and formulated to make a meaningful difference in patients' lives. Founded in 2015 and headquartered in Melbourne, Australia, we are expanding in the U.S. and worldwide to help more patients and their families. Incannex trades on the Nasdaq Global Market under the symbol IXHL.

InterK Peptide Therapeutics functions largely as a virtual company and located in Sydney, Australia.The company’s R&D program is supported by Contract Research Organisations located within Australia and overseas. All three assets share the ability to inhibit cancer growth in vivo in murine models but also differ significantly in their respective immunomodulating effects on expression of cytokines, cytokine receptors and regulation of signalling pathways within T cells, natural killer cells and antigen-presenting cells.

Invion is a clinical-stage life-sciences company that is leading the global clinical development of the Photosoft™ technology for the treatment of cancers. Invion has been appointed exclusive distributor and licensee in Australia and New Zealand of Photosoft™. The appointment has been made by technology licensor, The Cho Group, a Hong Kong based group that has funded and successfully commercialised a number of unique and advanced technologies. Via an R&D services agreement between the two entities, the research and clinical trials of Photosoft™ are funded by The Cho Group. Invion has an alliance with leading Australian medical research institute, Hudson Institute of Medical Research, for the Photosoft™ research program.

Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. We have a lead asset – ISLA-101 - that was initially developed by our wholly owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia’s investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Kinoxis Therapeutics Pty Ltd is a private, Australian-based, clinical-stage biotechnology company developing first-in-class therapeutics to address the escalating demand for safe and effective treatments for behavioural and psychological symptoms in neuropsychiatric disorders. Kinoxis’ lead candidate, KNX100, is being developed for the treatment of behavioural and psychological symptoms in neuropsychiatric disorders, including agitation and aggression in dementia, and several substance use disorders. KNX100 has a novel mechanism of action, interacting with disease relevant pharmacological, molecular, and neural targets, to modify the dysregulated brain systems linked with specific behavioural and psychological symptoms in neuropsychiatric disorders. The compound has an extensive pre-clinical data package consisting of multiple cross-species animal efficacy models conducted across several independent research organisations. Kinoxis has completed a Phase 1 study conducted under a US IND and have demonstrated KNX100 to be safe and tolerable in healthy volunteers. Currently, KNX100 is being investigated in the CARES-X Phase 2 clinical trial, a multi-site study in Australia focused exploring its safety, tolerability, and efficacy as a treatment for agitation in dementia. Kinoxis is also advancing clinical programs targeting stimulant, opioid, and alcohol use disorders. Notably, the alcohol use disorder program is being developed in collaboration with the National Institute on Alcohol Abuse and Alcoholism (NIAAA), while the opioid use disorder program has received significant funding from the US National Institute of Health/National Institute on Drug Abuse (NIH/NIDA). In addition to the KNX100 program, Kinoxis have a strategic partnership and licensing agreement with Boehringer Ingelheim to develop first-in-class oxytocin receptor targeting precision psychiatry treatments to improve the quality of life of people living with neuropsychiatric disorders.

Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immune tolerance. Kira Biotech has attracted venture capital funding and is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by well-known US-based rheumatologist and immunologist, Dr Dan Baker.

Lateral Pharma Pty Ltd Is a privately-owned Melbourne AU-based biotechnology company that commenced operations in May 2015 to repurpose LAT8881, a Phase 2 ready orally-available compound with extensive toxicology and human safety data, into new high potential pain and respiratory indications. Lateral aims to demonstrate efficacy in a human clinical Phase 2 proof-of-concept study using LAT8881 to treat neuropathic pain within the next 12 months. Lateral Pharma has discovered a new class of naturally-derived peptide motifs and their novel target family of proteins that restore normal tissue function in mammals under conditions of damage and cellular stress. Small synthetic peptides derived from growth hormone and at least three other proteins are active in animal models of neuropathic pain, osteoarthritis, obesity, COPD, severe influenza A and recently in initial data in SARS-CoV-2. Lateral has filed multiple patents protecting its intellectual property Lateral is focussed on developing its drugs for the treatment of Neuropathic pain but subject to additional funding will also explore development in respiratory diseases such as Influenza, SARS-CoV-2, COPD, Steroid resistant asthma, and Post-COVID Syndrome (Long-COVID).

Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.

Microba Life Sciences is a precision microbiome company driven to advance health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

Myrio Therapeutics ("Myrio Tx") is about to revolutionize the field of immuno-oncology by enabling antibody-based therapies to attack targets that are inside cells such as mutated cancer-causing and viral proteins. Proteins inside cells are routinely broken down into peptides which are displayed on the cell surface by Major Histocompatibility Complex (MHC), the targets of T-Cells. Myrio Tx’s protein-display system can discover antibodies against difficult to hit targets such as peptide-MHC complexes. This ability increases the number of addressable cancer or viral targets by a factor of ten. Based on fully-human sequences, discovered antibodies can be formatted to fit any purpose, from targeting CAR-T cells, antibody-drug conjugates, bispecifics or traditional antibodies. Myrio Tx's discovery platform can generate high affinity (low nM/pM) and highly selective scFv (antibody fragments) in a matter of days, allowing for rapid evaluation and optimization of product candidates. Myrio Tx is seeking partnerships to fully exploit the potential of its technology whilst also building an in-house portfolio of products.

NeuClone is a clinical stage biopharmaceutical company exclusively developing and commercialising high quality biosimilar products. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at the scale and price to meet demand in both new and established markets globally. NeuClone is differentiated by our deep and unmatched pipeline, as well as our Right From the Start® approach where we continually confirm biosimilarity at the earliest stages and throughout development.

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) is an Australian drug development company developing novel peptide-based pharmaceutical products that target a number of neurodegenerative conditions with high unmet medical need. Therapeutic indications include Alzheimer’s Disease, Multiple Sclerosis, Glaucoma and Post-Covid Lung Fibrosis. The companies lead compound, EmtinB works by effectively slowing down the death of dying cells and regenerating damaged nerves and tissue fibres.

OccuRx is a biotechnology company that specializes in developing innovative precision therapies for the treatment of inflammatory and fibrotic diseases.

OncoRes Medical is developing an intraoperative imaging tool that translates the surgeon's sense of touch into a microscale image - improving surgical accuracy and reducing complication rates. Founded in 2016, OncoRes is a medical device company funded by the Medical Research Commercialisation Fund, developing patent-protected technology in collaboration with leading researchers at the University of Western Australia, the Harry Perkins Institute of Medical Research and breast cancer surgeons from the Western Australian Department of Health. For more information, visit our website www.oncoresmedical.com or contact us at info@oncoresmedical.com.

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy. OncoSil Medical's lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹. We believe in our technology and its ability to have a truly positive impact in Oncology. OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications. Website link: oncosil.com References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.

Opthea Limited (ASX:OPT) is a public biotechnology company listed on the ASX and based in Melbourne, Australia. Opthea is developing OPT-302, a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacture and commercialisation of endomicroscopic digital imaging technology solutions for medical, translational and pre-clinical applications. Our unique technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. We are driven by delivering digital healthcare solutions giving healthcare providers and researchers high quality, live, microscopic images and associated tools. Our technology helps facilitate earlier detection and management of disease thus improving patient outcomes and reducing the cost of curative medicine and associated procedures within healthcare systems. We are united in the common pursuit of revolutionising healthcare with live digital microscopic solutions that enable immediate informed decisions, provide economic efficiencies within health systems and improve patient outcomes.

Percheron Therapeutics Limited (ASX: PER) is an international biotechnology company focused on the development of novel therapies for rare diseases. The company's lead program is ATL1102, an antisense oligonucleotide targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in 2H CY2024. The drug has previously reported promising results from an exploratory phase IIa study in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA. For more information, please contact info@PercheronTx.com.

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies. Cell Therapies OmniCAR: is a universal immune receptor platform enabling controllable cell activity and multi- antigen targeting with a single cell product. OmniCAR’s modular CAR system decouples antigen recognition from the cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to immune cells. OmniCAR is based on technology licensed from Penn and Oxford University; and other assets. Prescient is developing OmniCAR-T cells programs for next-generation CAR-T therapies for AML; Her2+ solid tumours, including breast, ovarian and gastric cancers; and GBM. CellPryme: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Targeted Therapies PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it has shown encouraging efficacy signals and safety. PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects.

Prota Therapeutics is an Australian biotech company established in 2016, dedicated to developing and commercializing cutting-edge oral immunotherapy treatments for food allergies. They have achieved significant quality of life improvements and clinical remission of peanut allergy in pediatric patients, with a 51 percent peanut allergy remission rate. The company has also secured a $21 million financing led by SPRIM Global Investments.

Psylo is a drug development company focused on next generation psychedelics; our goal is to make broadly accessible medicines as improved treatments to currently available SSRI medications, using psychedelic molecules as the starting point. We are building a pipeline of novel molecules with the ultimate goal of taking leading candidates through to clinical trials.

Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic applications. The company is focused on innovating the way we see and treat cancer, with a particular emphasis on HER-2 cancers. Radiopharm Theranostics has a strong team of executives and board members, and is actively engaged in investor relations and corporate governance. The company has also launched a joint venture with MD Anderson to focus on novel radiopharmaceuticals.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE:R9Q) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results to date. Recce Pharmaceuticals has manufacturing facilities in Australia and clinical research partners in the USA. Recce Pharmaceuticals has validated an automated process to manufacture its lead compound ahead of first-in-human clinical trials.

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

An RPM Business Augmented by R&D Respiri Limited (ASX:RSH, OTCQB:RSHUF) is a pioneering presence in the Remote Patient Monitoring (RPM) and MedTech sectors. The company uses its innovative respiratory technology with a disruptive business model as an RPM provider to offer the only RPM program for respiratory disorders. As a differentiated RPM provider, Respiri's mission is to improve health outcomes for patients with chronic diseases from cardiovascular, diabetes, obesity and, exclusively, respiratory disease. Respiri's globally unique medical device and its Remote Patient Monitoring services empower healthcare organisations to take action from patient data when needed, not only when scheduled. Respiri is strategically positioned to revolutionise chronic disease management globally and is focused on the US market, where RPM services are reimbursed by Current Procedural Terminology (CPT) Code reimbursement.

SDIP has unique patented platform that will revolutionize the world of fixation implants. SDIP`s compounds totally adsorb to the body when the host cells repair the damaged tissue avoiding unnecessary removal surgical interventions. In last two decades, there have been numerous attempts to develop bioresorbable fixation implants, but these devices have fallen short in providing the optimal degradation and also they degrade to acidic by-products causing local inflammation and delayed tissue regeneration. SDIP leaves no acidic/basic by-products behind. The properties of SDIP can be tuned to address different clinical needs in fixing a range of damaged soft and interface tissues. At SDIP Innovations, we are committed to stick to the customer-driven strategies tightly in the mission of revolutionizing the resorbable implants and provide a universally safer option for the patients.

Sementis Ltd is an Australian unlisted public biotechnology company based in Adelaide, South Australia and dedicated to research and development of new vaccines to tackle viruses and diseases globally. Sementis conducts it's research and development activities in partnership with the University of South Australia. We are using our proprietary Sementis Copenhagen Vector (SCV) and associated manufacturing system for the rapid development of effective vaccines to tackle infectious diseases of highest unmet medical needs as well as vaccines for pandemic preparedness. Our vaccine technology is also under evaluation for the prevention of allergies, with potential future applications also in cancer. Our lead vaccine candidates including a combination Zika-Chikungunya vaccine, a 'second generation' COVID-19 vaccine and therapeutic vaccine for peanut allergy. The SCV system couples a genetically engineered, non-replicative viral vector with a genetically engineered commercial manufacturing cell-line. The genes of disease antigens can be easily added to the viral vector, allowing for rapid adaptation of the vaccine against a single or multiple diseases and then manufacture on a commercial scale. The SCV is derived from a vaccinia virus strain used to eradicate smallpox, and concerns about safety have been addressed through our targeted genetic attenuation, thus making SCV vectored vaccines safe for use. Vaccines made using SCV are grown in our proprietary Chinese Hamster Ovary (CHO) cells, an industry standard cell line for large scale manufacturing with high yield and consistent batch quality. Extensive advanced pre-clinical studies have shown that vaccines using the SCV platform are safe and efficacious after a single vaccination, eliciting potent T and B-cell immunity, and long lasting protective vaccine immune response. We are now focussed on final GLP toxicology and immunogenicity studies in preparation for first in-human Phase I clinical trials.

We are a biopharmaceutical research and production company, based on the Sunshine Coast, Queensland. Established in 2012, we research, develop and produce high-quality, innovative, medical grade biopharmaceuticals based on the latest scientific research. Servatus has two drug research platforms: Engineered proteins for the treatment of autoimmune diseases, and microbial biotherapeutics for the treatment of inflammatory conditions and bacterial infections. Our protein research focuses on improving specific characteristics of existing therapeutic proteins. We carefully select proteins with clear clinical utility, and through rational redesign of key features, we improve bioavailbility and biological potency. We then rapidly clone and express the proteins in amounts suitable for clinical use, thus providing faster, more effective treatment of chronic auto immune diseases, such as rheumatoid arthritis and psoriasis, with fewer undesirable side effects. In parallel with our protein work, we also develop live microbial biotherapeutic treatments for microbiome-associated conditions, including but not limited to inflammatory bowel disease (IBD), arthritis, atopic dermatitis, and gastrointestinal infections (for example, C. diff and H.pylori infections). We utilise bacterial strains that have not been widely employed previously, but have demonstrated bioactive properties in the latest scientific research. These bacteria have been shown to inhibit pathogenic bacterial growth and infection, modulate immune responses, and regulate inflammatory signals. Bacterial candidates are developed to act directly at specific sites to treat specific ailments and diseases. Servatus currently holds patents for numerous microbial biotherapeutics and engineered proteins for autoimmune disease treatments Servatus Ltd derives its name from the patron saint St Servatus, a 4th century churchman and diplomat, who was invoked as a saint for his healing powers for a range of ailments. #biotech

S2N’s vision is a world where neuronal loss no longer means loss. Our regenerative medicine technology starts with the human hair follicle and ends with production of millions of pure neurons, all gene modification free. We aim to transform health, science and society.

In collaboration with RMIT University, Snoretox is developing the world’s first injectable solution to treat obstructive sleep apnoea and other conditions involving low muscle tone. Our game-changing technology is based on molecules of tetanus toxin, modified to ensure they work around the tetanus vaccine. Just as Botox uses tiny amounts of botulinum toxin to relax muscles, our prototype therapeutic uses minute amounts of safe modified tetanus toxin to achieve the opposite effect – muscle toning.

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Tessara Therapeutics Pty Ltd is a regenerative medicine company developing RealBrain® technology to break therapeutic barriers in the biopharmaceutical industry. RealBrain® technology is based on human mimetic 3D neural micro-tissues designed to have high physiological relevance, manufactured at industrial scale for unprecedented reproducibility. Priority applications include a high-throughput drug screening platform that includes a range of models of healthy and diseased brain tissue, and a regenerative medicine platform to develop next generation safe and efficacious tissue therapies for significant unmet neurological medical needs.

Vaxine was incorporated in 2002 as an Australian biotechnology company focussing on development of innovative vaccine technologies, with its lead product being its Advax delta inulin adjuvant. Supported by funding contracts from the National Institutes of Health Vaxine has developed a broad range of vaccines, all utilizing its Advax adjuvant technology for enhanced immunogenicity and protection. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, COVID-19, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy. Vaxine also has a veterinary division that is commercialising vaccine adjuvants tailored to specific animal health problems.

VivaZome Therapeutics Pty Ltd (ABN 59 602 230 964) is a privately-held Australian biotech company, with operational headquarters at the La Trobe University in Melbourne, Australia. VivaZome aims to develop and commercialise customised exosome-based therapies for debilitating and life-threatening disorders, with a focus on neurological disorders, retinal disease and ischaemic conditions. VivaZome is developing new technologies, intellectual property and manufacturing processes that apply generically to exosome therapies. These will underpin the Company’s development of specific exosome products for its target indications. The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech communities. VivaZome acknowledges the support of the Department of Industry and Science through the CRC-P program, and the contribution of its CRC-P partners: Australian National University, the University of Queensland, La Trobe University, Cytiva and SeerPharma Pty Ltd.